View PDF Version - RePub - Erasmus Universiteit Rotterdam

Chapter 1
11. Minguet S, Swamy M, Alarcon B, Luescher IF & Schamel WW (2007) Full activation of the T cell
receptor requires both clustering and conformational changes at CD3. Immunity 26(1):43-54.
12. Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H & Steinmetz M (1986) Transfer of
specificity by murine alpha and beta T-cell receptor genes. Nature 320(6059):232-238.
13. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS,
Restifo NP & Rosenberg SA (2003) High efficiency TCR gene transfer into primary human lymphocytes
affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter
the recognition of autologous melanoma antigens. J Immunol 171(6):3287-3295.
14. Schaft N, Willemsen RA, de Vries J, Lankiewicz B, Essers BW, Gratama JW, Figdor CG, Bolhuis RL,
Debets R & Adema GJ (2003) Peptide fine specificity of anti-glycoprotein 100 CTL is preserved
following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J
Immunol 170(4):2186-2194.
15. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RL, Melief
CJ, Huber C, Stauss HJ & Theobald M (2001) Circumventing tolerance to a human MDM2-derived
tumor antigen by TCR gene transfer. Nat Immunol 2(10):962-970.
16. Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P & Bolhuis RL (2000)
Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain
TCR. Gene Ther 7(16):1369-1377.
17. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA & Nishimura MI (1999) Efficient transfer of a
tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
J Immunol 163(1):507-513.
18. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA & Schumacher TN (2001) Immunotherapy
through TCR gene transfer. Nat Immunol 2(10):957-961.
19. Morris EC, Tsallios A, Bendle GM, Xue SA & Stauss HJ (2005) A critical role of T cell antigen
receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci
U S A 102(22):7934-7939.
20. Tahara H, Fujio K, Araki Y, Setoguchi K, Misaki Y, Kitamura T & Yamamoto K (2003) Reconstitution
of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally
expanded P815-infiltrating lymphocyte. J Immunol 171(4):2154-2160.
21. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE,
Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer
CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM & Rosenberg
SA (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and
targets normal tissues expressing cognate antigen. Blood 114(3):535-546.
22. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL,
Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA &
Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science 314(5796):126-129.
23. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA,
Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins
PF, Laurencot CM & Rosenberg SA (2011) T cells targeting carcinoembryonic antigen can mediate
regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19(3):620-
626.
24. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV,
Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF,
El-Gamil M, Schwarz SL, Laurencot C & Rosenberg SA (2011) Tumor regression in patients with
28